Why is Balaxi Pharma falling/rising?

As of 14-Aug, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 47.71, reflecting a decrease of 1.04 or 2.13%. The stock has underperformed its sector today by 2.51%, and while it is higher than its 5-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has shown a positive return of 4.15%, but its performance over the last month is negative at -2.69%. The stock has faced significant challenges, including a 56.01% drop in returns over the past year and a 49.8% decline in profits. Additionally, the recent negative financial results, particularly a substantial fall in profit before tax and profit after tax, have contributed to the stock's downward movement. The decrease in institutional investor participation, with a 7.16% reduction in their stake, further indicates a lack of confidence in the stock.
In the broader market context, the stock's performance has been notably poor compared to the benchmark, with a year-to-date return of -34.02% against the Sensex's positive return of 4.17%. This consistent underperformance over the last three years, alongside a significant drop in investor participation, suggests that market sentiment is unfavorable towards Balaxi Pharmaceuticals Ltd. Despite its strong long-term fundamentals, indicated by a high return on equity and attractive valuation, the recent financial results and declining investor interest have overshadowed these strengths, leading to a negative outlook for the stock.